This is the final post in a series based on the Complion webinar, The Future of the Clinical Research Industry, as presented by John Neal, CEO of PCRS Network. In that webinar, John explores a variety of factors that are driving the evolution of clinical research. This post looks at another of John Neal’s predictions.
Because sponsors are increasingly seeking efficiencies, and all stakeholders have an interest in minimizing the time required of, and the potential risk to, volunteers who participate in studies, there will be a decrease in the number of single drug studies in the future. [1]